Indications |
Oral Susceptible infections Adult: 600 mg once daily as a single or in 2 divided doses. Child: 14 mg/kg daily. Max: 600 mg daily.
Special Populations: Renal impairment: If CrCl is <30 mL/min, dose is 300 mg once daily. |
||||
Contraindications |
Hypersensitivity. | ||||
Warnings / Precautions |
Penicillin-sensitive patients; superinfection; seizure; pseudomembranous colitis; pregnancy, lactation; renal or hepatic insufficiency. | ||||
Adverse Reactions |
Headache, dizziness, fever; nausea, vomiting, diarrhoea, abdominal pain; rash; leukopaenia, thrombocytopaenia, haemolytic anaemia. Potentially Fatal: Anaphylaxis; renal and hepatic failure. |
||||
Drug Interactions |
Concomitant admin with antacids and Fe reduce the rate and extent of absorption. Probenecid reduces renal elimination. Antacids reduce rate and extent of absorption. See Below for More cefdinir Drug Interactions |
||||
Lab Interactions |
Administration with Fe supplements may color the urine red. | ||||
Mechanism of Actions |
Cefdinir binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death. Absorption: Absorbed from the GIT (oral); peak plasma concentrations after 2-4 hrs. Distribution: Widely into body tissues. Protein-binding: 60-70% Metabolism: Minimal metabolism. Excretion: Via the urine; 1.7 hrs (elimination half-life). Removed by dialysis. |
||||
Administration |
May be taken with or without food. |
||||
Storage Conditions |
Oral: Store at 25°C. | ||||
ATC Classification |
J01DD15 - cefdinir ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections. | ||||
Storage |
Oral: Store at 25°C. | ||||
Available As |
|
Cefdinir
Post Review about Cefdinir Click here to cancel reply.
Cefdinir Containing Brands
Cefdinir is used in following diseases
Drug - Drug Interactions of Cefdinir
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.